How Epstein-Barr Virus “Manipulates” The Tumoral Microenvironment in Hodgkin Lymphoma?

1. Levine PHAD, Berard CW, Carbone PP, et al. - Elevated antibody titers to Epstein-Barr virus in Hodgkin’s disease, 1971, Cancer 7:416–42110.1002/1097-0142(197102)27:2<416::AID-CNCR2820270227>3.0.CO;2-WSearch in Google Scholar

2. Mueller N, Evans A, Harris NL, et al. - Hodgkin’s disease and Epstein-Barr virus. Altered antibody pattern before diagnosis, 1989, N Engl J Med 20:689–69510.1056/NEJM198903163201103Open DOISearch in Google Scholar

3. Connelly RR, Christine BW - A cohort study of cancer following infectious Mononucleosis, 1974, Cancer Res 34:1172–11784842360Search in Google Scholar

4. Rosdahl N, Larsen SO, Clemmesen J - Hodgkin’s disease in patients with previous infectious mononucleosis: 30 years’ experience, 1974, BMJ 2:253–25610.1136/bmj.2.5913.253Search in Google Scholar

5. Hjalgrim H, Munksgaard L, Melbye M - Epstein-Barr virus and Hodgkin’s Lymphoma, 2002, Ugeskr Laeger 164:5924–5927Search in Google Scholar

6. Hjalgrim H, Ekstrom Smedby K, Rostgaard K, et al. -Infectious mononucleosis, childhood social environment, and risk of Hodgkin lymphoma, 2007, Cancer Res 67:2382–238810.1158/0008-5472.CAN-06-3566Search in Google Scholar

7. Anagnostopoulos I, Herbst H, Niedobitek G, et al. -Demonstration ofmonoclonal EBV genomes in Hodgkin’s disease and Ki-1-positive anaplastic large cell lymphoma by combined Southern blot and in situ hybridization, 1989, Blood 74:810–81610.1182/blood.V74.2.810.bloodjournal742810Search in Google Scholar

8. Coates PJ, Slavin G, D’Ardenne AJ - Persistence of Epstein-Barr virus in Reed-Sternberg cells throughout the course of Hodgkin’s disease, 1991, J Pathol 164:291–29710.1002/path.1711640404Search in Google Scholar

9. Glaser SL, Lin RJ, Stewart SL, et al. - Epstein-Barr virus-associated Hodgkin’s disease: epidemiologic characteristics in international data, 1997, Int J Cancer 70:375–382903364210.1002/(SICI)1097-0215(19970207)70:4<375::AID-IJC1>3.0.CO;2-TSearch in Google Scholar

10. Glaser SL, Jarrett RF - The epidemiology of Hodgkin’s disease, 1996, Baillieres Clin Haematol 9:401–41610.1016/S0950-3536(96)80018-7Search in Google Scholar

11. Chang KL, Albujar PF, Chen YY, et al. - High prevalence of Epstein-Barr virus in the Reed-Sternberg cells of Hodgkin’s disease occurring in Peru, 1993, Blood 81:496–50110.1182/blood.V81.2.496.496Search in Google Scholar

12. Weinreb M, Day PJ, Niggli F, et al. - The consistent association between Epstein-Barr virus and Hodgkin’s disease in children in Kenya, 1996, Blood 87:3828–383610.1182/blood.V87.9.3828.bloodjournal8793828Search in Google Scholar

13. Flavell KJ, Biddulph JP, Powell JE, et al. - South Asian ethnicity and material deprivation increase the risk of Epstein-Barr virus infection in childhood Hodgkin’s disease, 2001, Br J Cancer 85:350–35610.1054/bjoc.2001.1872236408211487264Search in Google Scholar

14. Armstrong AA, Alexander FE, Cartwright R, et al. -Epstein-Barr virus and Hodgkin’s disease: further evidence for the three disease hypothesis, 1998, Leukemia 12:1272–127610.1038/sj.leu.24010979697883Open DOISearch in Google Scholar

15. Jarrett RF, Gallagher A, Jones DB, et al. - Detection of Epstein-Barr virus genomes in Hodgkin’s disease: relation to age, 1991, J Clin Pathol 44:844–84810.1136/jcp.44.10.8444966721660054Open DOISearch in Google Scholar

16. Biggar RJ, Jaffe ES, Goedert JJ, et al. - Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS, 2006, Blood 108:3786–379110.1182/blood-2006-05-024109189547316917006Search in Google Scholar

17. Glaser SL, Clarke CA, Gulley ML, et al. - Population-based patterns of human immunodeficiency virus-related Hodgkin lymphoma in the Greater San Francisco Bay Area, 1988-1998, 2003, Cancer 98:300–30910.1002/cncr.1145912872349Search in Google Scholar

18. Bohlius J, Schmidlin K, Boue F, et al. - HIV-1-related Hodgkin lymphoma in the era of combination antiretroviral therapy: incidence and evolution of CD4(+) T-cell lymphocytes, 2011, Blood 117:6100–610810.1182/blood-2010-08-30153121368291Search in Google Scholar

19. Kowalkowski MA, Mims MP, Amiran ES, et al. - Effect of immune reconstitution on the incidence of HIV-related Hodgkin lymphoma, 2013, PLoS One 8:e7740910.1371/journal.pone.0077409378875824098586Search in Google Scholar

20. Gotti D, Danesi M, Calabresi A, et al. - Clinical characteristics, incidence, and risk factors of HIV-related Hodgkin lymphoma in the era of combination antiretroviral therapy, 2013, AIDS Patient Care STDs 27:259–26510.1089/apc.2012.042423600703Open DOISearch in Google Scholar

21. Price S, Shaw PA, Seitz A, et al. - Natural history of autoimmune lymphoproliferative syndrome associated with FAS gene mutations, 2014, Blood 123:1989–199910.1182/blood-2013-10-535393396838524398331Search in Google Scholar

22. McClain KL - Why do T cells cause so much trouble?, 2014, Blood 123:197810.1182/blood-2014-01-54947724677399Search in Google Scholar

23. Sanchez-Aguilera A, Montalban C, de la Cueva P, et al.- Tumor microenvironment and mitotic checkpoint are key factors in the outcome of classic Hodgkin lymphoma, 2006, Blood 108:662–66810.1182/blood-2005-12-512516551964Search in Google Scholar

24. Chetaille B, Bertucci F, Finetti P, et al. - Molecular profiling of classical Hodgkin lymphoma tissues uncovers variations in the tumor microenvironment and correlations with EBV infection and outcome, 2009, Blood 113:2765–377510.1182/blood-2008-07-16809619096012Search in Google Scholar

25. Steidl C, Lee T, Shah SP, et al. - Tumor-associated macrophages and survival in classic Hodgkin’s lymphoma, 2010, N Engl J Med 362:875–88510.1056/NEJMoa0905680289717420220182Search in Google Scholar

26. Steidl C, Farinha P, Gascoyne RD (2011a) Macrophages predict treatment outcome in Hodgkin’s lymphoma. Haematologica 96:186–18910.3324/haematol.2010.033316303168421282720Open DOISearch in Google Scholar

27. Aldinucci D, Celegato M, Casagrande N -Microenvironmental interactions in classical Hodgkin lymphoma and their role in promoting tumor growth, immune escape and drug resistance, 2016, Cancer Lett 380:243–25210.1016/j.canlet.2015.10.00726474544Search in Google Scholar

28. Fischer M, Juremalm M, Olsson N, et al. - Expression of CCL5/RANTES by Hodgkin and Reed-Sternberg cells and its possible role in the recruitment of mast cells into lymphomatous tissue, 2003, Int J Cancer 107:197–20110.1002/ijc.1137012949794Search in Google Scholar

29. Skinnider BF, Elia AJ, Gascoyne RD, et al. - Interleukin 13 and interleukin 13 receptor are frequently expressed by Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma, 2001, Blood 97:250–25510.1182/blood.V97.1.25011133768Open DOISearch in Google Scholar

30. Skinnider BF, Mak TW - The role of cytokines in classical Hodgkin Lymphoma, 2002, Blood 99:4283–429710.1182/blood-2002-01-009912036854Search in Google Scholar

31. Buri C, Korner M, Scharli P, et al. – CC chemokines and the receptors CCR3 and CCR5 are differentially expressed in the nonneoplastic leukocytic infiltrates of Hodgkin disease, 2001, Blood 97:1543–154810.1182/blood.V97.6.154311238088Open DOISearch in Google Scholar

32. Jundt F, Anagnostopoulos I, Bommert K, et al. -Hodgkin/Reed-Sternberg cells induce fibroblasts to secrete eotaxin, a potent chemoattractant for T cells and eosinophils, 1999, Blood 94:2065–20711047773610.1182/blood.V94.6.2065.418k15_2065_2071Search in Google Scholar

33. Sueur C, Lupo J, Germi R, et al. - Characterization of Epstein-Barr virus LMP1 deletion variants by next-generation sequencing in HIV-associated Hodgkinlymphoma (French ANRS CO16 LYMPHOVIR cohort), 2016, J Clin Virol 82:S89–S9010.1016/j.jcv.2016.08.178Search in Google Scholar

34. Kis LL, Takahara M, Nagy N, et al. - Cytokine mediated induction of the major Epstein-Barr virus (EBV)-encoded transforming protein, LMP-1, 2006, Immunol Lett 104:83–8810.1016/j.imlet.2005.11.003Search in Google Scholar

35. Dukers DF, Jaspars LH, Vos W, et al. - Quantitative Immunohistochemical analysis of cytokine profiles in Epstein-Barr virus-positive and -negative cases of Hodgkin’s disease, 2000, J Pathol 190:143–14910.1002/(SICI)1096-9896(200002)190:2<143::AID-PATH519>3.0.CO;2-5Search in Google Scholar

36. Barros MH, Hassan R, Niedobitek G - Tumor-associated macrophages in pediatric classical Hodgkin lymphoma: association with Epstein-Barr virus, lymphocyte subsets, and prognostic impact, 2012, Clin Cancer Res 18:3762–377110.1158/1078-0432.CCR-12-012922645050Open DOISearch in Google Scholar

37. Tan KL, Scott DW, Hong F, et al. – Tumor associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 intergroup trial, 2012, Blood 120:3280–328710.1182/blood-2012-04-421057Search in Google Scholar

38. Mantovani A, Schioppa T, Porta C, et al. - Role of tumor associated macrophages in tumor progression and invasion, 2006, Cancer Metastasis Rev 25:315–32210.1007/s10555-006-9001-7Open DOISearch in Google Scholar

39. Murdoch C, Muthana M, Coffelt SB, et al. - The role of myeloid cells in the promotion of tumour angiogenesis, 2008, Nat Rev Cancer 8:618–63110.1038/nrc2444Search in Google Scholar

40. Panico L, Ronconi F, Lepore M, et al. - Prognostic role of tumor-associated macrophages and angiogenesis in classical Hodgkin lymphoma, 2013, Leuk Lymphoma 54:2418–24252343268810.3109/10428194.2013.778405Search in Google Scholar

41. Koh YW, Park C, Yoon DH, et al. - CSF-1R expression in tumor associated macrophages is associated with worse prognosis in classical Hodgkin lymphoma, 2014, Am J Clin Pathol 141:573–58310.1309/AJCPR92TDDFARISUSearch in Google Scholar

42. Korkolopoulou P, Thymara I, Kavantzas N, et al. -Angiogenesis in Hodgkin’s lymphoma: a morphometric approach in 286 patients with prognostic implications, 2005, Leukemia 19:894–90010.1038/sj.leu.2403690Search in Google Scholar

43. Mainou-Fowler T, Angus B, Miller S, et al. - Micro-vessel density and the expression of vascular endothelial growth factor (VEGF) and platelet-derived endothelial cell growth factor (PdEGF) in classical Hodgkin lymphoma (HL), 2006, Leuk Lymphoma 47:223–23010.1080/0167482050030583816321851Search in Google Scholar

44. Doussis-Anagnostopoulou IA, Talks KL, Turley H, et al. -Vascular endothelial growth factor (VEGF) is expressed by neoplastic Hodgkin-Reed-Sternberg cells in Hodgkin’s disease, 2002, J Pathol 197:677–68310.1002/path.115112210089Search in Google Scholar

45. Muenst S, Hoeller S, Dirnhofer S, et al. - Increased programmed death 1+ tumor-infiltrating lymphocytes in classical Hodgkin lymphoma substantiate reduced overall survival, 2009, Hum Pathol 40:1715–172210.1016/j.humpath.2009.03.02519695683Search in Google Scholar

46. Yamamoto R, Nishikori M, Kitawaki T, et al. - PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma, 2008, Blood 111:3220–322410.1182/blood-2007-05-08515918203952Search in Google Scholar

47. Ansell SM, Lesokhin AM, Borrello I, et al. - PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma, 2015, N Engl J Med 372:311–319.10.1056/NEJMoa1411087434800925482239Search in Google Scholar